Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (272)
  • Open Access

    ARTICLE

    Coronary Artery Complications after Right Ventricular Outflow Tract Reconstruction Surgery

    Hye Won Kwon1,2, Mi Kyoung Song1, Sang Yun Lee1, Gi Beom Kim1, Sungkyu Cho2, Jae Gun Kwak2, Woong-Han Kim2, Whal Lee3, Eun Jung Bae1,*

    Congenital Heart Disease, Vol.17, No.3, pp. 281-295, 2022, DOI:10.32604/chd.2022.019065 - 03 May 2022

    Abstract Background: Mechanisms and clinical manifestations of coronary artery complications after right ventricular outflow tract reconstruction surgery are not well known. Methods: Patients who had coronary artery complications after pulmonary valve replacement or the Rastelli procedure at a single tertiary centre were retrospectively analysed. Results: Coronary artery complications were identified in 20 patients who underwent right ventricular outflow tract reconstruction surgery. The median age at diagnosis of coronary artery complication was 21 years (interquartile range: 13–25 years). Mechanisms of coronary artery complications were compression by adjacent materials in 12 patients, dynamic compression of intramural course of coronary artery… More >

  • Open Access

    ARTICLE

    Long-Term Outcome and Risk Factor Analysis of Surgical Pulmonary Valve Replacement in Congenital Heart Disease

    Woo Young Park1, Gi Beom Kim1,*, Sang Yun Lee1, Mi Kyoung Song1, Hye Won Kwon1, Hyo Soon An1, Eun Jung Bae1, Sungkyu Cho2, Jae Gun Kwak2, Woong-Han Kim2

    Congenital Heart Disease, Vol.17, No.3, pp. 335-350, 2022, DOI:10.32604/chd.2022.018666 - 03 May 2022

    Abstract Objectives: To establish long-term outcome of surgical pulmonary valve replacement (PVR) in congenital heart disease (CHD) and to identify risk factors for overall mortality, operative mortality, and repetitive PVR. Methods: This is a retrospective study of 375 surgical PVR in 293 patients who underwent surgical PVR for CHD between January 2000 and May 2020. We only included patients with index PVR with previous open-heart surgery regardless of the number of PVRs. The previous surgical history of patients who underwent PVR during the study period was also included. Patients who underwent the Rastelli operation, and those who… More >

  • Open Access

    ARTICLE

    Immediate and Long-Term Results of Transcatheter Closure of Patent Ductus Arteriosus—Comparison of Two Decades before and after Change in Antibiotic Infective Endocarditis Prophylaxis Guidelines

    Annina Dietrich1,2, Daniel Quandt1,2, Oliver Kretschmar1,2, Walter Knirsch1,2,*

    Congenital Heart Disease, Vol.17, No.2, pp. 215-230, 2022, DOI:10.32604/CHD.2021.017232 - 26 January 2022

    Abstract Objectives: To determine immediate and long-term follow-up of transcatheter closure of patent ductus arteriosus (PDA) in children. Background: National antibiotic prophylaxis (AP) guideline for infective endocarditis changed after 2009, the effect on practice of PDA closure is unknown. Methods: Observational single center study analyzing follow-up of PDA closure comparing two time periods before (2002–2009) and after (2010–2019) changes in AP guideline. Results: 332 patients (68.1% female), median (interquartile range) age 3.0 years (1.5–5.7) and body weight 14.0 kg (10.0–19.3), were enrolled. PDA morphology was conical type A (50.3%), window type B (1.2%), tubular type C (40.1%), complex type… More >

  • Open Access

    CASE REPORT

    A Rare Case of Infective Mediastinitis after Melody Valve Implantation

    Veronica Lorenz1, Karlien Carbonez2, Geoffroy de Beco1, Alain Poncelet1,*

    Congenital Heart Disease, Vol.17, No.2, pp. 187-192, 2022, DOI:10.32604/chd.2022.018350 - 26 January 2022

    Abstract Pulmonary valve implant is frequently necessary in children and adults with congenital heart disease. Infective endocarditis represents a rare but life-threatening complication after transcatheter pulmonary valve implantation. There are various treatments for native or prosthetic valve endocarditis. Surgical intervention, combined with intravenous antibiotic treatment, is of paramount importance, in case of concomitant mediastinal infection, in order to ensure the radical debridement of all infected tissue, avoiding any recurrent endocarditis. In this report, we describe a rare case of mediastinitis, associated with an infected endocarditis, occurring 8 months after Melody (Medtronic®, Minneapolis, USA) valve implant, successfully treated More >

  • Open Access

    CASE REPORT

    Transcatheter Device Closure of a Perimembranous Ventricular Septal Defect in Congenitally Corrected Transposition of the Great Arteries

    Catherine E. Tomasulo1,*, Lindsay S. Rogers1, Lauren Andrade1,2, Michael L. O’Byrne1,3,4

    Congenital Heart Disease, Vol.17, No.2, pp. 193-199, 2022, DOI:10.32604/chd.2022.017721 - 26 January 2022

    Abstract The majority of patients with congenitally corrected transposition of the great arteries, also known as transposition of the great arteries {S,L,L} have ventricular septal defects (VSD), most commonly perimembranous VSD (pmVSD). Transcatheter device closure of pmVSD in these patients has not been widely described. We present a case of device closure of pmVSD in L-TGA with an Amplatzer Duct Occluder II (ADOII) device using a deployment starting in the subpulmonary left ventricle. The case demonstrates some of the technical advantages of the ADOII device for VSD closure, specifically its low profile, symmetric shape, and soft More >

  • Open Access

    ARTICLE

    Multi-Institutional US Experience of the Occlutech© AFR Device in Congenital and Acquired Heart Disease

    Barry O’Callaghan1, Jenny Zablah1, Joseph Vettukattil2, Daniel Levi3,4, Morris Salem4, Allison Cabalka5, Jason Anderson6, Makram Ebeid6, Ryan Alexy7, Gareth J. Morgan1,*

    Congenital Heart Disease, Vol.17, No.1, pp. 107-116, 2022, DOI:10.32604/CHD.2022.018590 - 26 October 2021

    Abstract Objectives: To detail the US multi-institutional experience with the Occlutech© (Occlutech International AB, Helsingborg, Sweden) atrial flow regulator (AFR) in children and adults with acquired or congenital heart disease. Background: The creation of a long-term atrial communication is desirable in several cardiovascular disease phenotypes, most notably pulmonary arterial hypertension, disorders of increased left ventricular filling and increased cavopulmonary pressures in patients with a Fontan type circulation. Methods: Patients were identified for inclusion from the AFR device manufacturer database. Data was collected using a RedCap database following IRB approval. 8 weeks of follow up data was sought for… More >

  • Open Access

    ARTICLE

    Assessment of Reversibility in Pulmonary Hypertension Related to Congenital Heart Disease by Using Biomarkers and Clinical Features

    Liping Wang, Mingjie Zhang, Xi Chen, Yachang Pang, Jiaqi Liu, Zhuoming Xu*

    Congenital Heart Disease, Vol.17, No.1, pp. 87-97, 2022, DOI:10.32604/CHD.2022.018452 - 26 October 2021

    Abstract Background: Reversibility of pulmonary hypertension (PH) is closely related to the treatment options for and prognosis of children with congenital heart disease. Objective: We combined patient-specific clinical features including diagnosis, age and echocardiographic results, and biomarkers of pulmonary vascular dysfunction to explore the noninvasive methods that can be used to accurately evaluate the reversibility of pulmonary hypertension in congenital heart disease (PH-CHD). Methods: Based on the preoperative systolic pulmonary arterial pressure (sPAP), 70 CHD patients were divided into normal, PH-CHD suspected, and confirmed groups. Additionally, biomarkers of circulating endothelial cells (CECs), endothelin-1 (ET-1), and endothelial nitric oxide… More >

  • Open Access

    ARTICLE

    Characteristics of In-Hospital Patients with Congenital Heart Disease Requiring Rapid Response System Activations: A Japanese Database Study

    Taiki Haga1,*, Tomoyuki Masuyama2, Yoshiro Hayashi3, Takahiro Atsumi4, Kenzo Ishii5, Shinsuke Fujiwara6

    Congenital Heart Disease, Vol.17, No.1, pp. 31-43, 2022, DOI:10.32604/CHD.2022.017407 - 26 October 2021

    Abstract Objectives: This study aimed to study the characteristics of in-hospital deterioration in patients with congenital heart disease who required rapid response system activation and identify risk factors associated with 1-month mortality. Methods: We retrospectively analysed data from a Japanese rapid response system registry with 35 participating hospitals. We included consecutive patients with congenital heart disease who required rapid response system activation between January 2014 and March 2018. Logistic regression analyses were performed to examine the associations between 1-month mortality and other patient-specific variables. Results: Among 9,607 patients for whom the rapid response system was activated, only 82… More >

  • Open Access

    ARTICLE

    What Is the Relation between Aerobic Capacity and Physical Activity Level in Adults with Congenital Heart Disease?

    Kelly Ferri1,*, Maite Doñate2,3, Mireia Parra2,3, Guillermo R. Oviedo1, Myriam Guerra-Balic1, Laia Rojano-Doñate4, Nicole Blackburn5, Ricard Serra-Grima2,3

    Congenital Heart Disease, Vol.16, No.6, pp. 585-595, 2021, DOI:10.32604/CHD.2021.016189 - 08 July 2021

    Abstract Background: Aerobic capacity (AC) in adults with congenital heart disease (CHD) is often reduced, mainly due to low confidence levels towards physical activity (PA). The main objective of this study was to estimate the association between PA level and AC (measured as peak of oxygen consumption, VO2peak) in adults with CHD. Methods: A total of 183 individuals (83 women and 100 men; mean (SD) age 36.9 (11.0) years old) from Vall d’Hebron Hospital, Barcelona-Spain in 2019, participated in this cross-sectional study. The AC was assessed by cardiopulmonary exercise testing (CPET) using a treadmill ramp protocol. Considering values… More >

  • Open Access

    ARTICLE

    Cardiopulmonary Response to Exercise at High Altitude in Adolescents with Congenital Heart Disease

    Lukas Minder1, Markus Schwerzmann1,2, Thomas Radtke1,3, Hugo Saner1, Prisca Eser1, Matthias Wilhelm1, Jean-Paul Schmid1,4,*

    Congenital Heart Disease, Vol.16, No.6, pp. 597-608, 2021, DOI:10.32604/CHD.2021.016031 - 08 July 2021

    Abstract Objective: To extend our knowledge on tolerance of acute high-altitude exposure and hemodynamic response to exercise in adolescents with congenital heart disease (AscCHD) without meaningful clinical or functional restriction. Methods: A symptom limited cardiopulmonary exercise stress test and a non-invasive cardiac output measurement during steady state exercise were performed at 540 m and at 3454 m a.s.l. Symptoms of acute mountain sickness were noted. Results: We recruited 21 healthy controls and 16 AscCHD (59% male, mean age 14.7 ± 1.1 years). Three subjects (2 controls, 1 AscCHD) presented light symptoms of acute mountain sickness (dizziness and headache). During… More >

Displaying 61-70 on page 7 of 272. Per Page